ContraFect Corporation

CFRXQ

US2123264093

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 01:56:45 2024-04-23 pm EDT			5-day change	1st Jan Change
0.0191 ^USD	+6.00%		-9.05%	-36.33%

Apr. 19	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 12	North American Morning Briefing : Big Banks Kick -2-	DJ

ContraFect Corporation(NasdaqCM:CFRX) dropped from Russell 2500 Index

June 25, 2021 at 12:00 am EDT

Latest news about ContraFect Corporation

North American Morning Briefing : Stock Futures -2-	Apr. 19	DJ
North American Morning Briefing : Big Banks Kick -2-	Apr. 12	DJ
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited	Apr. 05	DJ
Bidding Procedure Approved for ContraFect Corporation	Feb. 09	CI
Motion for Asset Sale Filed by ContraFect Corporation	Jan. 11	CI
ContraFect Corporation Announces Resignation of Michael Messinger as Chief Financial Officer	Dec. 05	CI
ContraFect Corporation Announces Management Resignations	Dec. 05	CI
ContraFect Corporation Announces Resignation of Michael Messinger as Chief Executive Officer	Dec. 05	CI
ContraFect Corporation Filed for Bankruptcy	Dec. 04	CI
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	Nov. 20	DJ
ContraFect Corporation Announces Chief Executive Officer Changes	Nov. 15	CI
ContraFect Corporation Announces Executive Changes	Nov. 15	CI
ContraFect Corporation Appoints Michael Messinger as Chief Financial Officer	Nov. 15	CI
ContraFect Corporation Implements Restructuring Plan Resulting in Reduction to Workforce from A Total of 23 Employees to Five Employee	Nov. 15	CI
ContraFect Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
North American Morning Briefing : Stock Futures Dip as Inflation Data Looms	Nov. 13	DJ
ContraFect Corporation(OTCPK:CFRX) dropped from S&P TMI Index	Nov. 13	CI
ContraFect Corporation(OTCPK:CFRX) dropped from NASDAQ Composite Index	Nov. 08	CI
ContraFect Submits Investigational New Drug Application for Bacterial Pneumonia Treatment	23-09-18	MT
North American Morning Briefing : Focus Shifts to -2-	23-08-21	DJ
ContraFect Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
North American Morning Briefing : Stock Futures Firmer Despite More China Stress	23-08-14	DJ
ContraFect Corporation(NasdaqCM:CFRX) dropped from Russell Microcap Value Index	23-06-23	CI
ContraFect Corporation(NasdaqCM:CFRX) dropped from Russell 3000E Value Index	23-06-23	CI
ContraFect Corporation(NasdaqCM:CFRX) dropped from Russell Microcap Growth Index	23-06-23	CI

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its CF-301 is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CONTRAFECT CORPORATION	-36.33%	193K
IQVIA HOLDINGS INC.	+3.25%	42.11B
LONZA GROUP AG	+48.83%	40.08B
MODERNA, INC.	+8.44%	40B
CELLTRION, INC.	-10.82%	26.87B
ICON PUBLIC LIMITED COMPANY	+8.23%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.19%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.16%	11.94B
MEDPACE HOLDINGS, INC.	+33.47%	11.66B
UNITED THERAPEUTICS CORPORATION	+7.23%	11.01B

Other Biotechnology & Medical Research